4/10
08:05 am
ESPR
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
High
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
4/10
06:47 am
ESPR
Rating for ESPR
High
Report
Rating for ESPR
4/10
06:47 am
ESPR
Rating for ESPR
High
Report
Rating for ESPR
3/25
01:00 pm
ESPR
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
3/25
08:06 am
ESPR
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
3/25
07:33 am
ESPR
Rating for ESPR
Medium
Report
Rating for ESPR
3/25
07:33 am
ESPR
Rating for ESPR
Medium
Report
Rating for ESPR
2/27
03:12 pm
ESPR
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
2/27
02:46 pm
ESPR
Rating for ESPR
Low
Report
Rating for ESPR
2/27
02:46 pm
ESPR
Rating for ESPR
Low
Report
Rating for ESPR